Auwerx Johan
Institut de Génétique et Biologie Moléculaire et Cellulaire, Centre National de la Recherche Scientifique, Institut Nationale de la Sauté et de la Recherche Médicale, Université Louis Pasteur, 67404 Illkirch, France.
Am J Physiol Gastrointest Liver Physiol. 2002 Apr;282(4):G581-5. doi: 10.1152/ajpgi.00508.2001.
The peroxisome proliferator-activated receptor gamma (PPAR gamma) has recently been implicated in the pathogenesis of inflammatory bowel disease (IBD) and colon cancer. The observation that PPAR gamma agonists, through immune modulation, protect against inflammatory processes in the intestine justified their expedient evaluation in the clinical management of IBD. PPAR gamma agonists are reported to have both tumor-promoting and -inhibiting effects in models of colon cancer. These differences can, in part, be explained by PPAR gamma-independent effects of PPAR gamma agonists and by differences in the models used. Because it is still unclear how PPAR gamma impacts on colon cancer, careful monitoring of patients receiving PPAR gamma agonists and additional basic research is indicated before recommendations on the use of PPAR gamma ligands in colon cancer can be made.
过氧化物酶体增殖物激活受体γ（PPARγ）最近被认为与炎症性肠病（IBD）和结肠癌的发病机制有关。PPARγ激动剂通过免疫调节对肠道炎症过程具有保护作用，这一观察结果证明了它们在IBD临床治疗中进行快速评估的合理性。据报道，PPARγ激动剂在结肠癌模型中具有促肿瘤和抑肿瘤两种作用。这些差异部分可以通过PPARγ激动剂的非PPARγ依赖性作用以及所用模型的差异来解释。由于目前尚不清楚PPARγ如何影响结肠癌，因此在就PPARγ配体在结肠癌中的应用提出建议之前，需要对接受PPARγ激动剂治疗的患者进行仔细监测，并开展更多基础研究。
